These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33817847)

  • 1. Risk mitigation in Crohn's disease and ulcerative colitis: Session four summary.
    Leong RW
    J Gastroenterol Hepatol; 2021 Apr; 36 Suppl 1():27-28. PubMed ID: 33817847
    [No Abstract]   [Full Text] [Related]  

  • 2. European Crohn's and Colitis Organisation Topical Review on IBD in the Elderly.
    Sturm A; Maaser C; Mendall M; Karagiannis D; Karatzas P; Ipenburg N; Sebastian S; Rizzello F; Limdi J; Katsanos K; Schmidt C; Jeuring S; Colombo F; Gionchetti P
    J Crohns Colitis; 2017 Mar; 11(3):263-273. PubMed ID: 27797918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Adalimumab vasculitis in a patient with Crohn's disease].
    Muñoz Villafranca C; Izu Belloso RM; Bravo Rodriguez MT; Basterra Olabarrieta S
    Gastroenterol Hepatol; 2013 Apr; 36(4):296-7. PubMed ID: 23522950
    [No Abstract]   [Full Text] [Related]  

  • 4. Biological therapy for Crohn's disease in a liver transplant patient.
    Bendezú García RA; Rodríguez Manrique MA; Hernández Martínez A; Lázaro Sáez M; Patrón Román GO; Amat Alcaraz S; Vega Sáenz JL
    J Dig Dis; 2013 Oct; 14(10):564-6. PubMed ID: 23437819
    [No Abstract]   [Full Text] [Related]  

  • 5. Update on idiopathic colitides.
    Strobel S; Abreu MT
    Curr Opin Gastroenterol; 2013 Jan; 29(1):60-5. PubMed ID: 23207597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative Considerations in Inflammatory Bowel Disease.
    McKenna NP; Lightner AL
    Surg Clin North Am; 2019 Dec; 99(6):1083-1094. PubMed ID: 31676049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacologic therapy of Crohn's disease and ulcerative colitis].
    Banai J
    Orv Hetil; 2000 May; 141(22):1171-7. PubMed ID: 10853345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
    Lam MC; Bressler B
    Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events in IBD therapy: the 2018 update.
    Quezada SM; McLean LP; Cross RK
    Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1183-1191. PubMed ID: 30791788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Not Available].
    Bliampti AL; Seidelin JB; Burisch J
    Ugeskr Laeger; 2024 Apr; 186(18):. PubMed ID: 38704716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?
    Hindryckx P; Vande Casteele N; Novak G; Khanna R; D'Haens G; Sandborn WJ; Danese S; Jairath V; Feagan BG
    J Crohns Colitis; 2018 Jan; 12(1):105-119. PubMed ID: 28961959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews.
    Khanna R; Chande N; Vermeire S; Sandborn WJ; Parker CE; Feagan BG
    Inflamm Bowel Dis; 2016 Jul; 22(7):1737-43. PubMed ID: 27306074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease.
    Doherty G; Katsanos KH; Burisch J; Allez M; Papamichael K; Stallmach A; Mao R; Berset IP; Gisbert JP; Sebastian S; Kierkus J; Lopetuso L; Szymanska E; Louis E
    J Crohns Colitis; 2018 Jan; 12(1):17-31. PubMed ID: 28981623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
    Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B
    Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia.
    Ooi CJ; Hilmi I; Banerjee R; Chuah SW; Ng SC; Wei SC; Makharia GK; Pisespongsa P; Chen MH; Ran ZH; Ye BD; Park DI; Ling KL; Ong D; Ahuja V; Goh KL; Sollano J; Lim WC; Leung WK; Ali RAR; Wu DC; Ong E; Mustaffa N; Limsrivilai J; Hisamatsu T; Yang SK; Ouyang Q; Geary R; De Silva JH; Rerknimitr R; Simadibrata M; Abdullah M; Leong RWL;
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1296-1315. PubMed ID: 30848854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis comparing the efficacy and adverse events of biologics and thiopurines for Crohn's Disease after surgery for ulcerative colitis.
    Yadav A; Kurada S; Foromera J; Falchuk KR; Feuerstein JD
    Dig Liver Dis; 2018 Oct; 50(10):1004-1011. PubMed ID: 29903546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Questions and answers about the management of Crohn's disease and ulcerative colitis with vedolizumab.
    Hinojosa Del Val J; Barreiro-de Acosta M
    Gastroenterol Hepatol; 2019 Dec; 42(10):650-656. PubMed ID: 31635855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.
    Hagan M; Cross RK
    Expert Opin Drug Saf; 2015; 14(9):1473-9. PubMed ID: 26138111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.